NASDAQ: PLUR · Life Sciences · 4 alerts · CIK 1158780
Share price
$1.04Close, Nov 16
Market cap
$12.8M
Shares outstanding
12.34MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Pluri Inc. filings on SEC EDGAR ↗
Pluri Inc. reported a significant increase in net loss to $15.39 million for the quarter ended September 30, 2026, primarily driven by a $10.9 million charge for acquired in-process research and development related to the Fishway Transaction. Despite the loss, revenues grew to $759,000 compared to $316,000 in the prior year, and the company successfully raised capital through share issuances and a SAFE agreement.
Pluri Inc. entered into a partnership agreement with ZEO ScientifiX to grant ZEO an exclusive license to manufacture and commercialize Pluri's regenerative medicine portfolio in the United States. In exchange, Pluri will receive a 50% equity stake in ZEO and the right to designate four out of seven board members, while ZEO will receive approximately 9% of Pluri's outstanding common shares.
Pluri Insider Alexandre Weinstein Manieu Buys $1.25M of Stock
Alexandre Weinstein Manieu bought 833,334 shares of Pluri Inc. at $1.50 a share, worth $1.25M in total on Oct 23, 2026. Shares held after the trade: 2,083,334 (+66.7%).
Pluri Inc. entered into a Securities Purchase Agreement with its largest shareholder, Chutzpah Holdings LP, to issue 833,334 common shares and warrants to purchase an additional 833,334 shares. The $1.25 million aggregate purchase price was satisfied by an advance payment previously received by the company in June 2026. The shares were priced at $1.50 per share, with the warrants carrying an exercise price of $1.65.